Circio Holding ASA: Mandatory notification of trade (share lending in connection with private placement)
Oslo, Norway, 15 September 2026: Reference is made to the stock exchange announcement published by Circio Holding ASA ("Circio" or the "Company", OSE: CRNA) regarding the completion of a private placement (the "Private Placement") raising gross proceeds of approximately NOK 200 million through the issuance of 16,865,000 new shares (the "Offer Shares") at a subscription price of NOK 11.80 per share.
The Offer Shares allocated in the Private Placement will be settled on a delivery-versus-payment (DVP) basis using existing and unencumbered shares in the Company that are already listed on Euronext Oslo Børs, pursuant to share lending agreements entered into between the Company, a group of existing shareholders, including Sølen AS, a company closely associated with primary insider and board member Thomas Falck, as share lenders and Pareto Securities AS (as manager in the Private Placement).
Please see the enclosed attachments for further information.
This information is subject to the disclosure requirements in Article 19 of Regulation (EU) 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act.
For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com
Lubor Gaal, CFO Phone: +34 683 34 3811 Email: lubor.gaal@circio.com
About Circio Building circular RNA expression systems for enhanced gene and cell therapies
Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.
Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 60-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.